<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Wei SC</submitter><funding>NIH Cancer Center</funding><funding>NIDDK NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>Cancer Prevention and Research in Texas</funding><funding>NCI NIH HHS</funding><funding>the Vanderbilt Mouse Metabolic Phenotyping Center</funding><funding>NIH</funding><funding>NCI Cancer Center</funding><funding>NIH HHS</funding><funding>NIGMS NIH HHS</funding><pagination>614-625</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8041233</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>11(3)</volume><pubmed_abstract>Immune checkpoint inhibitors (ICI) targeting CTLA4 or PD-1/PD-L1 have transformed cancer therapy but are associated with immune-related adverse events, including myocarditis. Here, we report a robust preclinical mouse model of ICI-associated myocarditis in which monoallelic loss of &lt;i>Ctla4&lt;/i> in the context of complete genetic absence of &lt;i>Pdcd1&lt;/i> leads to premature death in approximately half of mice. Premature death results from myocardial infiltration by T cells and macrophages and severe ECG abnormalities, closely recapitulating the clinical and pathologic hallmarks of ICI-associated myocarditis observed in patients. Using this model, we show that &lt;i>Ctla4&lt;/i> and &lt;i>Pdcd1&lt;/i> functionally interact in a gene dosage-dependent manner, providing a mechanism by which myocarditis arise</pubmed_abstract><journal>Cancer discovery</journal><pubmed_title>A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.</pubmed_title><pmcid>PMC8041233</pmcid><funding_grant_id>5P30 CA68485–19</funding_grant_id><funding_grant_id>T32 GM152284</funding_grant_id><funding_grant_id>F30CA236157</funding_grant_id><funding_grant_id>R01 HL155990</funding_grant_id><funding_grant_id>U24 DK059637</funding_grant_id><funding_grant_id>P30CA16672</funding_grant_id><funding_grant_id>R35 HL144980</funding_grant_id><funding_grant_id>F30 CA236157</funding_grant_id><funding_grant_id>T32 GM007347</funding_grant_id><funding_grant_id>R1203</funding_grant_id><funding_grant_id>T32 GM007569</funding_grant_id><funding_grant_id>2 U24 DK059637–16</funding_grant_id><funding_grant_id>P30 CA016672</funding_grant_id><funding_grant_id>S10 OD023475</funding_grant_id><funding_grant_id>R01 HL141466</funding_grant_id><funding_grant_id>R01 CA227481</funding_grant_id><funding_grant_id>P30 CA068485</funding_grant_id><funding_grant_id>R01CA227481</funding_grant_id><funding_grant_id>U2C DK059637</funding_grant_id><funding_grant_id>R56 141466</funding_grant_id><funding_grant_id>T32GM007347</funding_grant_id><funding_grant_id>R56 HL141466</funding_grant_id><funding_grant_id>R01 141466</funding_grant_id><pubmed_authors>Anang NAS</pubmed_authors><pubmed_authors>Meijers WC</pubmed_authors><pubmed_authors>Rao X</pubmed_authors><pubmed_authors>Wescott EC</pubmed_authors><pubmed_authors>Courand PY</pubmed_authors><pubmed_authors>Wang J</pubmed_authors><pubmed_authors>Zhao Y</pubmed_authors><pubmed_authors>Axelrod ML</pubmed_authors><pubmed_authors>Knollmann BC</pubmed_authors><pubmed_authors>Himmel LE</pubmed_authors><pubmed_authors>Lehmann L</pubmed_authors><pubmed_authors>Whitley E</pubmed_authors><pubmed_authors>Atolagbe OT</pubmed_authors><pubmed_authors>Moslehi JJ</pubmed_authors><pubmed_authors>Balko JM</pubmed_authors><pubmed_authors>Ehrlich LIR</pubmed_authors><pubmed_authors>Wei SC</pubmed_authors><pubmed_authors>Srinivasan J</pubmed_authors><pubmed_authors>Allison JP</pubmed_authors><pubmed_authors>Sharma P</pubmed_authors><pubmed_authors>Mancuso JJ</pubmed_authors><pubmed_authors>Johnson DB</pubmed_authors><pubmed_authors>Lebrun-Vignes B</pubmed_authors><pubmed_authors>Li Y</pubmed_authors><pubmed_authors>Screever EM</pubmed_authors><pubmed_authors>Wleklinski MJ</pubmed_authors><pubmed_authors>Salem JE</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor-Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention.</name><description>Immune checkpoint inhibitors (ICI) targeting CTLA4 or PD-1/PD-L1 have transformed cancer therapy but are associated with immune-related adverse events, including myocarditis. Here, we report a robust preclinical mouse model of ICI-associated myocarditis in which monoallelic loss of &lt;i>Ctla4&lt;/i> in the context of complete genetic absence of &lt;i>Pdcd1&lt;/i> leads to premature death in approximately half of mice. Premature death results from myocardial infiltration by T cells and macrophages and severe ECG abnormalities, closely recapitulating the clinical and pathologic hallmarks of ICI-associated myocarditis observed in patients. Using this model, we show that &lt;i>Ctla4&lt;/i> and &lt;i>Pdcd1&lt;/i> functionally interact in a gene dosage-dependent manner, providing a mechanism by which myocarditis arise</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Mar</publication><modification>2026-05-02T11:36:49.091Z</modification><creation>2022-02-11T10:06:14.126Z</creation></dates><accession>S-EPMC8041233</accession><cross_references><pubmed>33257470</pubmed><doi>10.1158/2159-8290.CD-20-0856</doi><doi>10.1158/2159-8290.cd-20-0856</doi></cross_references></HashMap>